In DLBCL, Survivin is overexpressed in up to 60% of the cases, and is associated with advanced clinical stage, reduced remission rate, shortened event‐free survival, as well as increased chemoresistance and relapse 8, 9. Here, BIRC5 is linked to diffuse large B-cell lymphoma.